c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas

被引:39
作者
Hernández, L
Hernández, S
Beà, S
Pinyol, M
Ferrer, A
Bosch, F
Nadal, A
Fernández, PL
Palacín, A
Montserrat, E
Campo, E
机构
[1] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Anat Pathol Lab, Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, IDIBAPS, Dept Hematol, Barcelona, Spain
[3] Hosp Casa Maternitat, Barcelona, Spain
关键词
c-myc; overexpression; mantle cell lymphoma;
D O I
10.1038/sj.leu.2401599
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cyclin D1 is a weak oncogene that cooperates with c-myc activation in the development of B cell lymphomas in transgenic animals. Cyclin D1 is constantly overexpressed in human mantle cell lymphomas (MCL). However, the status of c-myc gene in these tumors is not known. We have examined the c-myc mRNA expression and genomic alterations, including mutational analysis of exon 1, intron 1, and exon 2 regulatory elements, in a series of 33 MCL, 22 typical and 11 blastoid variants. In addition, c-myc alterations were also examined in 56 nodal non-Hodgkin's lymphomas (NHL), c-myc mRNA overexpression was found in 38% (11/29) of MCL with a slightly higher frequency in blastoid Variants (5/10, 50%) than in typical cases (6/19, 31%). Genetic alterations were only found in one blastoid MCL showing a three-fold c-myc gene amplification. In other nodal NHL, c-myc overexpression was found in 24% (7/29) of indolent tumors but in 70% (19/27) of aggressive variants. c-myc Genetic alterations detected in these cases were gene rearrangement and hypermutations in one Burkitt's lymphoma, and individual point mutations in intron 1 or exon 2 in 1/19 (5%) indolent and 7/16 (44%) aggressive variants. These results indicate that c-myc is overexpressed in a subset of MCL, but structural gene alterations are less frequent than in other nodal NHL.
引用
收藏
页码:2087 / 2093
页数:7
相关论文
共 41 条
[1]   CYCLIN D1 TRANSGENE IMPEDES LYMPHOCYTE MATURATION AND COLLABORATES IN LYMPHOMAGENESIS WITH THE MYC GENE [J].
BODRUG, SE ;
WARNER, BJ ;
BATH, ML ;
LINDEMAN, GJ ;
HARRIS, AW ;
ADAMS, JM .
EMBO JOURNAL, 1994, 13 (09) :2124-2130
[2]  
BOSCH F, 1994, BLOOD, V84, P2726
[3]  
BRENNSCHEIDT U, 1994, LEUKEMIA, V8, P897
[4]  
Campo E, 1999, SEMIN HEMATOL, V36, P115
[5]   MONOCLONAL-ANTIBODIES AGAINST RECOMBINANT PARTS OF THE KI-67 ANTIGEN (MIB-1 AND MIB-3) DETECT PROLIFERATING CELLS IN MICROWAVE-PROCESSED FORMALIN-FIXED PARAFFIN SECTIONS [J].
CATTORETTI, G ;
BECKER, MHG ;
KEY, G ;
DUCHROW, M ;
SCHLUTER, C ;
GALLE, J ;
GERDES, J .
JOURNAL OF PATHOLOGY, 1992, 168 (04) :357-363
[6]   MUTATIONS IN THE 1ST EXON ARE ASSOCIATED WITH ALTERED TRANSCRIPTION OF C-MYC IN BURKITT-LYMPHOMA [J].
CESARMAN, E ;
DALLAFAVERA, R ;
BENTLEY, D ;
GROUDINE, M .
SCIENCE, 1987, 238 (4831) :1272-1275
[7]  
CLARK HM, 1994, CANCER RES, V54, P3383
[8]  
Dreyling MH, 1997, CANCER RES, V57, P4608
[9]   C-MYC MESSENGER-RNA EXPRESSION IN NON-HODGKINS-LYMPHOMAS [J].
FELLBAUM, C ;
RADASZKIEWICZ, T ;
RUHRI, C ;
PUTZ, B ;
LEHMACHER, W ;
HOFLER, H .
VIRCHOWS ARCHIV B-CELL PATHOLOGY INCLUDING MOLECULAR PATHOLOGY, 1992, 62 (01) :61-68
[10]   Cdc25 cell-cycle phosphatase as a target of c-myc [J].
Galaktionov, K ;
Chen, XC ;
Beach, D .
NATURE, 1996, 382 (6591) :511-517